UroGen Pharma Ltd.'s stock surged 6.09% during intraday trading on Monday, following a positive analyst action that boosted investor sentiment.
The rally comes after H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on UroGen Pharma to $45 from $40 while maintaining a Buy rating on the shares. This upward revision in the price target represents increased confidence in the company's prospects and valuation.
Analyst price target increases often signal positive expectations for a company's future performance and can trigger buying activity among investors who follow analyst recommendations.